New clinical data for AstraZeneca's first-in-class poly(ADP-ribose) polymerase (PARP) inhibitor olaparib has raised the bar for a bevy of would-be competitors.The FDA granted accelerated approval to olaparib in 2014 for fourth-line treatment of BRCA-mutated ovarian cancer, but the drug came under pressure last

中文翻译：

---

PARP抑制剂不断涌现

阿斯利康一流的聚（ADP-核糖）聚合酶（PARP）抑制剂olaparib的新临床数据提高了一系列潜在竞争对手的门槛.2014年，FDA批准了olaparib的加速批准，用于olaparib的四线治疗BRCA突变的卵巢癌，但该药最后受到压力